Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
28.86
-0.10 (-0.35%)
Aug 13, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $38.33. The average 1-year stock price forecast is 32.81% higher than the current stock price, while the lowest is $23 (-20.30%) and the highest is $47 (+62.86%).
Price Target: $38.33 (+32.81%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 10 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Hold Reiterates $29 | Hold | Reiterates | $29 | +0.49% | Aug 11, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $22 → $23 | Hold | Reiterates | $22 → $23 | -20.30% | Aug 10, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $34 → $42 | Buy | Reiterates | $34 → $42 | +45.53% | Aug 10, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $47 | Buy | Maintains | $47 | +62.86% | Aug 6, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 6, 2026 |
Financial Forecast
Revenue This Year
75.67M
from 247.00M
Decreased by -69.36%
Revenue Next Year
66.58M
from 75.67M
Decreased by -12.01%
EPS This Year
-3.65
from -3.29
EPS Next Year
-3.25
from -3.65
EPS and Forward PE are based on non-GAAP adjusted numbers.